|
WO2021067702A1
|
|
Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists
|
|
WO2021025985A1
|
|
Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression
|
|
WO2021007487A1
|
|
Formulations of t-type calcium channel modulators and methods of use thereof
|
|
US2020377499A1
|
|
Ion channel modulators
|
|
US2020377507A1
|
|
Ion channel modulators
|
|
US2020377506A1
|
|
Compounds and their methods of use
|
|
WO2020227097A1
|
|
Kcnt1 inhibitors and methods of use
|
|
WO2020227101A1
|
|
Kcnt1 inhibitors and methods of use
|
|
WO2020180955A1
|
|
Methods for the treatment of perimenopause and menopause
|
|
WO2020132521A1
|
|
Compositions and methods for the treatment of kcnt1 related disorders
|
|
WO2020124094A1
|
|
Methods for the treatment of depression
|
|
WO2020069322A1
|
|
Ion channel modulators
|
|
US10562930B1
|
|
Salts and crystal forms of gaba-a positive allosteric modulator
|
|
KR20210024500A
|
|
Ion channel modulator
|
|
AR115458A1
|
|
ION CHANNEL MODULATORS
|
|
US2020179358A1
|
|
Compounds and their methods of use
|
|
US2020085838A1
|
|
Methods of treating epilepsy and neurodevelopmental disorders
|
|
WO2018187480A1
|
|
Compounds and their methods of use
|
|
US2020247793A1
|
|
Compounds and their methods of use
|
|
WO2018118101A1
|
|
T-type calcium channel modulators and methods of use thereof
|
